QyScore
Commercial- Indications
- Alzheimer's disease, Multiple sclerosis, Parkinson's disease
Company intelligence / Profile preview
Qynapse has commercialized its flagship product, QyScore®, which provides over 200 automated measures of neuroinflammation and neurodegeneration from MRI scans. The solution supports improved diagnosis accuracy in CNS diseases such as Alzheimer’s. Clinical results show significant reduction in image reading variability and increased diagnostic precision. The company also develops predictive tools to support clinical trial design but does not itself develop therapeutics.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Qynapse.